Mobile

A late stage clinical trial to investigate the efficacy and safety of AZD9291 versus Placebo in patients with stage IB-IIIA non-small cell lung carcinoma, following complete tumour resection with or w...

Update Il y a 4 ans
Reference: EUCTR2015-000662-65

A late stage clinical trial to investigate the efficacy and safety of AZD9291 versus Placebo in patients with stage IB-IIIA non-small cell lung carcinoma, following complete tumour resection with or without adjuvant chemotherapy

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To assess the efficacy of AZD9291 compared to placebo as measured by disease free survival (DFS)

Inclusion criteria

  • Stage IB-IIIA non-small cell lung carcinoma, with a centrally confirmed, common sensitising EGFR mutations (Ex19del and L858R either alone or in combination with other EGFR mutations), following complete tumour resection with or without adjuvant chemotherapy

Links